Summary:
PASSAGE (Multiple Sclerosis)
A global study is being conducted with patients who are starting new treatment for relapsing forms of Multiple Sclerosis (MS). This research study will be used to evaluate the long-term safety of a specific MS treatment or another disease modifying therapy (DMT). Patients who enroll will be invited to participate in an optional patient reported outcome (PRO) sub-study and will complete a set of questionnaires at routine visits.
To join this study, you must have a relapsing form of MS. This study is for patients who will be starting a specific study medication at the start of the study or are starting another DMT or started within 6 months of study entry. Patients previously or currently treated with cytotoxic agents (e.g. chemotherapy or radiotherapy) or natalizumab (Tysabri) cannot participate in this study.
Qualified participants and their insurance will not be billed for study-related visits, such as those to the office and to other diagnostic centers.